SpyGlass Pharma, Inc. 8-K

What Happened

• On March 9, 2026, SpyGlass Pharma, Inc. (SGP) filed a Form 8‑K (Item 8.01) to announce positive top-line 12‑month clinical updates for its Bimatoprost Drug Pad‑IOL System from the ongoing Phase 1/2 trial. The company attached a press release as Exhibit 99.1 to the filing. The Form 8‑K was signed by Jean‑Frédéric Viret, Ph.D., Chief Financial Officer.

Key Details

• Filing date: March 9, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Program: Bimatoprost Drug Pad‑IOL System (ophthalmic drug/device candidate).
• Trial stage: Phase 1/2 — the update covers 12‑month, top‑line clinical results.
• Supporting material: Press release attached as Exhibit 99.1; the 8‑K itself references the positive top‑line update but does not include detailed numerical data within the filing.

Why It Matters

• Positive 12‑month top‑line updates signal clinical progress for SpyGlass’s lead ophthalmic program and represent an operational milestone publicly disclosed via an 8‑K. For investors, this confirms advancement of the Phase 1/2 study and sets the stage for any forthcoming detailed data releases or development milestones. The filing does not report financial results or specific efficacy/safety figures — investors should review the attached press release (Exhibit 99.1) or company communications for full data and next steps.